Mike Lattanzi, MD

Dr. Mike Lattanzi, of Texas Oncology, specializes in hematology and medical oncology, and is board certified in internal medicine and medical oncology.

Articles by Mike Lattanzi, MD

Advancing RCC Treatment: Trials to Watch and Promising Novel Approaches

Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | October 22, 2024

In the final part of this roundtable series, the panelists share their thoughts on the most anticipated upcoming trials.

Overcoming Access and Treatment Hurdles in Community and Academic RCC Care

Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | October 22, 2024

In the fifth segment of this roundtable, the panelists discuss the challenges and barriers of ipi-nivo therapy.

Subcutaneous vs IV Nivolumab: A New Frontier in RCC Treatment Delivery

Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | October 22, 2024

The fourth segment of this roundtable series focuses on the potential benefits of subcutaneous nivolumab versus IV nivolumab.

What Matters Most: Shared Decision-Making and Treatment Endpoints in RCC

Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | December 30, 2024

The third segment of this roundtable focuses on key treatment endpoints when deciding between IO-IO and IO-TKI regimens.

Biomarkers in RCC Treatment: The Role of Sarcomatoid Features and Emerging Technologies

Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | December 30, 2024

The panel delves into the utility of sarcomatoid features, PD-L1 status, and emerging biomarkers like KIM 1 and ctDNA.

Balancing Risks and Rewards in RCC: IO Combinations for Different Patient Profiles

Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | December 30, 2024

An expert panel debates the latest strategies for optimizing first-line treatment for advanced renal cell carcinoma.